Table 3: Univariate and multivariate regression for potential risk factors of COVID-19 in patients with IBD .

Covariates (Ref)	Univariable analysis			Multivariable analysis
	OR	95% CI	P value	OR	95% CI	P value
Ulcerative colitis (Crohn’s disease)	0.85	(0.52-1.38)	0.519	-	-	-
Gender, (Male)	1.23	(0.79-1.92)	0.349	-	-	-
Age, (0-9)	Ref.			Ref.	-	-
10-19 years	1.61	(0.20-12.78)	0.651	1.55	(0.11-20.17)	0.736
20-29 years	1.59	(0.21-12.04)	0.652	1.09	(0.09-13.29)	0.943
30-39 years	2.61	(0.34-19.70)	0.352	1.85	(0.15-22.72)	0.631
40-49 years	1.37	(0.17-11.01)	0.763	1.19	(0.09-15.60)	0.894
50-59 years	2.14	(0.26-17.34)	0.475	2.54	(0.18-35.50)	0.488
60-69 years	0.72	(0.04-11.91)	0.822	2.25	(0.05-89.86)	0.665
≥70 years	5.62	(0.47-66.32)	0.170a	3.33	(0.13-82.38)	0.461
Number of comorbidities, (0)
1	1.43	(0.85-2.38)	0.171a	1.28	(0.59-2.78)	0.520
2	1.69	(0.71-4.05)	0.232	.83	(0.20-3.45)	0.803
≥3	3.92	(1.60-9.63)	0.003a	1.01	(0.09-10.30)	0.992
IBD disease activity (Remission)
Mild	1.66	(0.79-3.46)	0.177a	.86	(0.34-2.15)	0.749
Moderate	.85	(0.48-1.53)	0.611	.91	(0.43-1.91)	0.812
Severe	2.21	(0.95-5.15)	0.065a	1.12	(0.36-3.44)	0.844
Concomitant therapy for IBD (None)
5-ASA	.91	(0.56-1.46)	0.703	-	-	-
Corticosteroids	3.12	(1.67-5.80)	0.000#	1.87	(0.80-4.36)	0.147
Thiopurines, 6 MP, MTX	1.05	(0.66-1.67)	0.819	-	-	-
Anti-TNF without Thiopurines, 6 MP, MTX	1.95	(1.16-3.27)	0.011a	2.56	(0.97-6.71)	0.055*
Anti-TNF with Thiopurines, 6 MP, MTX	1.58	(0.82 -3.045)	0.165a	.51	(0.15-1.67)	0.268

Abbreviations: IBD, Inflammatory bowel diseases; 5-ASA, 5-Aminosalicylic acid; AZA, Azathioprine; MTX, Methotrexate

^a Variables with P value less than 0.2 in univariable analysis were entered into the multivariable analysis.

*Statistically significant.